KMDA May 2024 2.500 put
| Previous Close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.50 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.0100 - 0.0100 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 13 |
Insider MonkeyKamada Ltd. (NASDAQ:KMDA) Q1 2024 Earnings Call Transcript
Kamada Ltd. (NASDAQ:KMDA) Q1 2024 Earnings Call Transcript May 8, 2024 Kamada Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Kamada Limited First Quarter 2024 Earnings Conference Call. At this […]
GlobeNewswireKamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
Revenues for First Quarter of 2024 were $37.7 Million, Representing a 23% Increase Year-over-YearFirst Quarter 2024 Adjusted EBITDA of $7.5 Million, Representing a 96% Increase Year-over-YearMomentum Primarily Driven by U.S. Sales of the Company’s Two Most Significant Catalysts, KEDRAB® and CYTOGAM®Strong First Quarter Results and Positive Outlook for Remainder of 2024 Support Increase of Full-Year Revenue Guidance to $158 Million-$162 Million and Adjusted EBITDA to $28 Million-$32 Million Confe
- GlobeNewswire
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024. Kamada management will host an
